Clearmind Medicine finishes dosing 24 trial participants
- Clearmind Medicine has successfully finalized patient dosing for all 24 healthy participants across Cohorts 1 to 4 in Part A of its ongoing Phase I/II clinical trial.
- The clinical evaluation of the company's proprietary, non-hallucinogenic compound, CMND-100, is targeting Alcohol Use Disorder under FDA oversight at elite global institutions.
- Interim safety data from the initial three cohorts continue to display a strong tolerability profile, backed by recent corporate financing and pipeline expansions.
Clinical-stage biotech company Clearmind Medicine (NASDAQ:CMND) has successfully completed the dosing of all 24 healthy participants in Part A of its FDA-regulated Phase I/II trial evaluating its proprietary compound, CMND-100, for the treatment of Alcohol Use Disorder.
This major clinical achievement follows a series of positive regulatory updates earlier this spring, contrasting with the company's historical position as an early-stage research firm.
The multicenter, double-blind study was executed across elite medical centers, including Yale School of Medicine and Johns Hopkins University School of Medicine, following a recent June 12 agreement to issue $1 million in convertible promissory notes to bolster capital reserves.
Looking ahead, the company plans to leverage this safety data to advance into the next phase of clinical trials, and at the time of publication, shares of Clearmind Medicine were trading at $3.58, representing an increase of 12.93% on the day.
This clinical milestone caps off a busy operational stretch that included a 1-for-10 reverse share split executed on May 19, 2026, alongside new patent filings in Japan and Europe to expand its global intellectual property footprint into depression and post-traumatic stress disorder treatments.
